Zovaglutide: Dosing Protocols

Investigational Status#

Zovaglutide (ZT-002) is an investigational medication that has not yet received regulatory approval. All dosing information is derived from clinical trial protocols and published results. Dosing should only occur within the context of clinical trials.

Phase 2 Trial Dosing#

The phase 2 trial enrolled 303 overweight or obese subjects who were randomized to five treatment groups:

Dose Escalation#

All groups included a dose escalation period before reaching their maintenance dose, consistent with standard GLP-1 RA practice to minimize gastrointestinal side effects during initiation.

Key Dosing Observations#

• 160 mg Q4W: The once-monthly 160 mg dose achieved 13.8% weight loss at 24 weeks, offering the best balance of efficacy and convenience
• Q2W vs Q4W: The biweekly 160 mg regimen achieved up to 14.4% weight loss, marginally higher than monthly dosing
• Dose-response: Clear dose-response relationship across all groups
• Weight loss trajectory: The 24-week results may not represent plateau; further weight loss could occur with continued treatment

Administration#

Injection Technique#

Zovaglutide is administered as a subcutaneous injection:

1. Inject subcutaneously in the abdomen or thigh
2. Rotate injection sites between monthly doses
3. Follow dose escalation schedule to minimize GI events
4. Administer on the same day each month for consistency

Once-Monthly Convenience#

The monthly dosing schedule represents a significant practical advantage:

• 12 injections per year vs 52 for weekly GLP-1 RAs
• Reduced injection burden may improve long-term adherence
• Simplified treatment schedule for patients
• Potentially better suited for patients who are needle-averse

Comparison with Other GLP-1 RA Dosing#

Dosing Context#

Zovaglutide belongs to the Metabolic category of research peptides. Dosing protocols for Zovaglutide are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.

Research Protocols#

The following dosing protocols have been documented in clinical research for Zovaglutide:

Obesity (Weight Management)#

Dose: Once-monthly subcutaneous injection. Phase 2 evaluated 80 mg and 160 mg Q4W (once every 4 weeks), and 80 mg and 160 mg Q2W (every 2 weeks). The 160 mg Q4W dose achieved 13.8% weight loss at 24 weeks.

Frequency: Once monthly (Q4W) subcutaneous injection

Duration: Ongoing (24 weeks evaluated in phase 2)

Dose escalation period included before reaching maintenance dose. The Q4W regimen is preferred for patient convenience while the Q2W regimen showed higher weight loss at higher doses.

Protocol Quick Reference#

Primary Use: Obesity and overweight (weight management)

Dosing Summary: 80-160 mg administered Once monthly (Q4W) for Ongoing.

Route of Administration: subcutaneous (Once monthly).

Timing Notes: Monthly subcutaneous injection with dose escalation

Cycle Duration: Ongoing.

Storage: Likely refrigerated (2-8 degrees C). Consult product-specific guidance.

Additional Considerations#

• Investigational drug - not yet approved by any regulatory authority
• Dose escalation required to minimize GI side effects
• Once-monthly dosing is a key convenience advantage

Reconstitution and Preparation#

Formulation details not publicly disclosed. Administered as a subcutaneous injection.

Injection Sites#

Recommended injection sites for Zovaglutide include:

• Abdomen
• Thigh

Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.

Storage Requirements#

Storage requirements not publicly disclosed. Likely requires refrigeration based on peptide formulation standards.

Related Reading#

• Zovaglutide overview and research guide
• Zovaglutide side effects profile
• Zovaglutide research evidence